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Background: Placebo and nocebo effects have been observed in relation to many interventions in sport. 
Given variance in response, a key question is whether individual difference variables identify likely 
‘responders.’ Hypothetically, such a variable might be the person’s intention to use the intervention. We 
aimed to explore relationships between athletes' intention to use sport supplements and their 
responses to a placebo/nocebo intervention. Methods: Participants completed a single-item measure of 
intention to use sport supplements (‘intending’, ‘undecided’ or ‘not intending’) prior to 5×20-m sprints. 
Participants were then randomised to Placebo (n=219), Nocebo (n=168) and Control (n = 134) 
conditions. Participants in Placebo and Nocebo conditions were administered a capsule deceptively 
presented as a sport supplement that would have a positive (Placebo) or negative (Nocebo) effect on 
performance. Controls were provided with no instructions and received no capsule. After 20 minutes, all 
participants completed another set of 5×20-m sprints. Results: Among ‘intending to use’ participants, 
the Placebo treatment was associated with faster times than the Nocebo treatment (P=0.023, Cohen’s d 
[d]=0.34). In the Placebo treatment, ‘intending to use’ participants were significantly faster than ‘not 
intending to use’ participants (P=0.004, d=0.49), as were ‘intending to use’ participants in relation to 
‘undecided’ participants in the Nocebo treatment (P=0.044, d=0.44). No significant differences in 
performance by intention were observed in the Control condition. Conclusions: Placebo and nocebo 
responses appear to be mediated by the participant’s intention to use supplements. These findings have 
value in explaining placebo/nocebo responses, and should be tested in clinical medical settings. 
